Top investment themes by experts for this year
Markets have been on a roll since April 2013, supported by ample liquidity infused by foreign institutional investors.
Four reasons why buying into Ranbaxy yet may not be a wise decision
For Ranbaxy, the worst may seem to be over with the US settlement. However, it may still not be a wise decision to jump into buying the stock.
Sensex rises 31 pts; banking and healthcare stocks gain
Sun Pharma at Rs 963.65 was the biggest gainer by rising 2.03 per cent followed by ONGC by 1.78 per cent at Rs 326.50 and Bharti Airtel by 1.78 per cent at Rs 317.20.
|
No comments:
Post a Comment